Skip to main content
Premium Trial:

Request an Annual Quote

Nuvera Biosciences Licenses PGx Assays to Veridex

NEW YORK (GenomeWeb News) – Nuvera Biosciences has licensed pharmacogenomic assays that it has developed to Veridex, which will commercialize the tests.

The multi-gene assays were developed for predicting patient response to tamoxifen therapy and taxane-containing chemotherapy in breast cancer. Woburn, Mass.-based Nuvera developed the assays in collaboration with the University of Texas MD Anderson Cancer Center.

Under terms of the agreement, Veridex, which is a Johnson & Johnson company, will pay Nuvera an upfront fee, milestone payments over the next several years based on commercialization and revenues, and royalties on sales. Nuvera said that it will continue to support test validation through its expertise in diagnostics and bioinformatics and through its partnerships with MD Anderson and other cancer centers.

Veridex also will complete clinical studies on the tests and intends to commercialize the assays worldwide.

"We believe the uniqueness of our tests is not just their therapy-directed focus but that they can potentially be combined with Veridex tests into a single test platform that could enable important, effective decisions from a single tumor sample," Nandan Padukone, president and CEO of Nuvera, said in a statement.